HIV Infection, AIDS, and Cancer

+ -Text Size


Previous Topic

To learn more


Bonnet F, Burty C, Lewden C, et al; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 Survey. Clin Infect Dis. 2009;48:633-639.

Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Case Definitions for AIDS among Adolescents and Adults. MMWR. 1992;41(RR-17). Accessed at on January 3, 2012.

Centers for Disease Control and Prevention. HIV/AIDS Basic Statistics. Accessed at on January 3, 2012.

Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR. 2005;54(No. RR-9).

Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10:412-426.

Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.

Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma. 2006;47:1822-1829.

Diamond C, Taylor TH, Im T, et al. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. Curr HIV Res. 2006;4:375-378.

Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54:78-84.

Franceschi S, Lise M, Clifford GM, et al; Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-422.

Gifford AL, Lorig K, Laurent D, Gonzalez V. Living Well with HIV and AIDS. Palo Alto, Ca: Bull Publishing; 1997.

Guiguet M, Boué F, Cadranel J, et al; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol. 2009;10:1152-1159.

Kaplan JE, Benson C, Holmes KH, et al; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207. Accessed at on January 5, 2012.

Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-2559.

Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-1963.

Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.

Thompson MA, Aberg JA, Cahn P, Montaner JS, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.

UNAIDS (Joint United Nations Global AIDS Programme). 2008 Report on the global AIDS epidemic, Executive Summary. Accessed at on January 3, 2012.

Last Medical Review: 02/01/2012
Last Revised: 07/05/2012